AngioDynamics (ANGO) Reports In-Line Q2 EPS; Trims FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
AngioDynamics (ANGO) PT Cut at Piper Jaffray
January 8, 2016 7:34 AM ESTAngioDynamics (NASDAQ: ANGO) met expectations for its Q2 (Nov) revenues and earnings, but cut guidance for the remainder of the year as the vascular access business has been adjusting to a Q3 recall from last year. Piper Jaffray analyst, Thomas Gunderson, lowered numbers as a result.
The Morpheus product was taken off the market, and the sales force diverted effort to try to retain customers. Not only was retention more... More
